Advaxis Completes Dosing Vanguard Group In Phase II Cervical Dysplasia (CIN) Study

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has completed the nine (9) doses to be administered to the three (3) vanguard patients in the low dose group of its phase II cervical dysplasia clinical trial study…


Read more

Related posts

Leave a Reply